NO20051804L - GHRH analoger - Google Patents

GHRH analoger

Info

Publication number
NO20051804L
NO20051804L NO20051804A NO20051804A NO20051804L NO 20051804 L NO20051804 L NO 20051804L NO 20051804 A NO20051804 A NO 20051804A NO 20051804 A NO20051804 A NO 20051804A NO 20051804 L NO20051804 L NO 20051804L
Authority
NO
Norway
Prior art keywords
ghrh
relates
present
analogs
human
Prior art date
Application number
NO20051804A
Other languages
English (en)
Inventor
Pierette Gaudreau
Original Assignee
Ct Hospitaller De Universite D
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct Hospitaller De Universite D filed Critical Ct Hospitaller De Universite D
Publication of NO20051804L publication Critical patent/NO20051804L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/60—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/25—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • Reproductive Health (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)

Abstract

Foreliggende oppfinnelse angår veksthormon frigivende hormon (GHRH) analoger. Mer bestemt angår oppfirmelsen syntetiske GHRH analoger med 29 aminosyrer eller mer, som viser samtidig en øket resistens overfor proteolyse og en høy bindingsaffinitet til human GHRH reseptor i in vitro studier, sammenlignet med humant nativt GHRN (1 29)NH2. Foreliggende oppfirmelse angår også anvendelsen av disse analogene for spesifikk stimulering av in vivo GH fiigiving så vel som fremstilling av et medikament for behandling av GH-mangel-relaterte tilstander. Foreliggende oppfirmelse fremskaffer også en fremgangsmåte for initiering av GHRH induserte biologiske virkninger i et pattedyr.
NO20051804A 2002-09-18 2005-04-13 GHRH analoger NO20051804L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41134002P 2002-09-18 2002-09-18
PCT/CA2003/001418 WO2004027064A2 (en) 2002-09-18 2003-09-17 Ghrh analogues

Publications (1)

Publication Number Publication Date
NO20051804L true NO20051804L (no) 2005-04-13

Family

ID=32030666

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20051804A NO20051804L (no) 2002-09-18 2005-04-13 GHRH analoger

Country Status (13)

Country Link
US (2) US20060128615A1 (no)
EP (1) EP1539959A2 (no)
JP (1) JP2006504694A (no)
KR (1) KR20050071498A (no)
CN (1) CN1688696A (no)
BR (1) BR0314619A (no)
CA (1) CA2496687A1 (no)
MX (1) MXPA05002991A (no)
NO (1) NO20051804L (no)
NZ (1) NZ539218A (no)
RU (1) RU2005111253A (no)
WO (1) WO2004027064A2 (no)
ZA (1) ZA200502221B (no)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2118123T3 (en) 2007-01-31 2016-01-25 Dana Farber Cancer Inst Inc Stabilized p53 peptides and uses thereof
US8592377B2 (en) 2007-03-28 2013-11-26 President And Fellows Of Harvard College Stitched polypeptides
CN101678083A (zh) * 2007-04-04 2010-03-24 瑟瑞技术公司 Ghrh分子的药物制剂
US20090088380A1 (en) * 2007-07-12 2009-04-02 Pierrette Gaudreau Ghrh analogs and therapeutic uses thereof
US20100267636A1 (en) * 2009-04-20 2010-10-21 Theratechnologies Inc. Use of cytochrome p450-metabolized drugs and grf molecules in combination therapy
US20100267635A1 (en) * 2009-04-20 2010-10-21 Theratechonolgies Inc. Use of protease inhibitors and grf molecules in combination therapy
WO2011153491A2 (en) 2010-06-03 2011-12-08 University Of Miami Agonists of growth hormone releasing hormone as effectors for survival and proliferation of pancreatic islets
ES2711526T3 (es) 2010-08-13 2019-05-06 Aileron Therapeutics Inc Macrociclos peptidomiméticos
US20130261058A1 (en) * 2010-09-16 2013-10-03 University Of Miami Acceleration of wound healing by growth hormone releasing hormone and its agonists
KR20140027284A (ko) 2011-04-21 2014-03-06 쎄러테크놀로지스 인코포레이티드 성장 호르몬 방출 인자(grf) 유사체 및 이의 용도
TW201806968A (zh) 2011-10-18 2018-03-01 艾利倫治療公司 擬肽巨環化合物
US9079974B2 (en) 2011-12-21 2015-07-14 The University Of Miami GH-RH analogs with potent agonistic effects
BR112014020103A2 (pt) 2012-02-15 2018-10-09 Aileron Therapeutics, Inc. macrociclos peptidomiméticos
EP2819688A4 (en) 2012-02-15 2015-10-28 Aileron Therapeutics Inc TRIAZOL AND THIOETHER-COUPLED PEPTIDOMIMETIC MACROCYCLES
WO2013190520A2 (en) 2012-06-22 2013-12-27 The General Hospital Corporation Gh-releasing agents in the treatment of vascular stenosis and associated conditions
WO2014071241A1 (en) 2012-11-01 2014-05-08 Aileron Therapeutics, Inc. Disubstituted amino acids and methods of preparation and use thereof
WO2014100816A2 (en) 2012-12-21 2014-06-26 University Of Miami Ghrh agonists for islet cell transplantation and function and the treatment of diabetes
US9855312B2 (en) 2012-12-21 2018-01-02 University Of Miami GHRH agonists for the treatment of ischemic disorders
US20150174207A1 (en) * 2013-12-24 2015-06-25 University Of Miami Methods for treating cancer with ghrh agonists
CN105198966B (zh) * 2014-06-26 2019-06-21 中国人民解放军军事医学科学院毒物药物研究所 GnRH类似物-细胞毒分子缀合物、其制备方法及用途
EP3197478A4 (en) 2014-09-24 2018-05-30 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
CN104558150B (zh) * 2014-11-04 2017-12-15 广东药学院 一类生长激素释放激素类似肽及其在制备治疗不孕不育药物中的应用
WO2016154058A1 (en) 2015-03-20 2016-09-29 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
WO2017181277A1 (en) * 2016-04-19 2017-10-26 Griffon Pharmaceuticals Inc. Pegylated bioactive peptides and uses thereof
CN111407884B (zh) * 2019-06-24 2021-12-07 浙江大学 促生长激素释放激素激动剂ghrh-a在制备抗衰老药物中的用途
CN111533800B (zh) * 2020-03-18 2021-08-31 浙江湖州纳福生物医药有限公司 新型生长激素释放激素类似肽改构和二聚体化制备及其应用
CN121627804B (zh) * 2026-02-04 2026-04-17 湖南中晟全肽生物科技股份有限公司 一种促进生长激素释放的多肽及其应用

Family Cites Families (115)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US652047A (en) * 1899-09-23 1900-06-19 Nelson T Shields Artificial tooth.
US4411890A (en) * 1981-04-14 1983-10-25 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
US3862925A (en) * 1973-07-05 1975-01-28 American Home Prod Preparation of somatotropin release inhibiting factor and intermediates therefor
US3842067A (en) * 1973-07-27 1974-10-15 American Home Prod Synthesis of(des-asn5)-srif and intermediates
US4301066A (en) * 1980-05-08 1981-11-17 American Home Products Corp. Preparation of (D-Trp 6)-LH-RH via the heptapeptide H-Ser-Tyr-D-Trp-Leu-Arg-Pro-Gly-NH2
US4439356A (en) * 1981-03-03 1984-03-27 Syva Company Unsymmetrical fluorescein derivatives
US4517181A (en) * 1982-09-15 1985-05-14 The Salk Institute For Biological Studies Mammalian PGRF
US4595676A (en) * 1983-04-26 1986-06-17 The Salk Institute For Biological Studies Rat hypothalamic GRF
US4563352A (en) * 1982-10-04 1986-01-07 The Salk Institute For Biological Studies Human pancreatic GRF
US4529595A (en) * 1983-01-13 1985-07-16 The Salk Institute For Biological Studies GRF Analogs
US4518586A (en) * 1983-01-13 1985-05-21 The Salk Institute For Biological Studies GRF Analogs III
US4628043A (en) * 1983-04-26 1986-12-09 The Salk Institute For Biological Studies Hypothalamic GRF agonists
US4610976A (en) * 1983-08-29 1986-09-09 The Salk Institute For Biological Studies Porcine GRF
US4605643A (en) * 1984-03-02 1986-08-12 The Salk Institute For Biological Studies Ovine GRF
US4585756A (en) * 1983-10-12 1986-04-29 The Salk Institute For Biological Studies Bovine GRF
US4626523A (en) * 1983-09-13 1986-12-02 The Salk Institute For Biological Studies GRF analogs II
US4528190A (en) * 1983-10-25 1985-07-09 The Salk Institute For Biological Studies GRF Analogs IV
US4622312A (en) * 1984-09-24 1986-11-11 Hoffmann-La Roche Inc. Growth hormone releasing factor analogs
EP0189673B1 (en) * 1984-12-24 1990-09-26 Sumitomo Pharmaceuticals Company, Limited Stable growth hormone releasing factor preparation
US4734399A (en) * 1985-08-06 1988-03-29 Hoffmann-La Roche Inc. Growth hormone releasing factor analogs
US4689318A (en) * 1985-08-29 1987-08-25 The Salk Institute For Biological Studies GRF analogs
US4784987A (en) * 1987-01-13 1988-11-15 The Salk Institute For Biological Studies GRF analogs VI
US4843064A (en) * 1987-01-13 1989-06-27 The Salk Institute For Biological Studies GRF analogs V
US5877277A (en) * 1987-09-24 1999-03-02 Biomeasure, Inc. Octapeptide bombesin analogs
US5756458A (en) * 1989-06-16 1998-05-26 Pharmacia & Upjohn Company Stabilized potent GRF analogs
US5137872A (en) * 1989-09-18 1992-08-11 Pitman-Moore, Inc. Growth hormone-releasing factor analogs
CA2084061A1 (en) * 1991-04-09 1992-10-10 Arthur M. Felix Growth hormone releasing factor analogs
US5262519A (en) * 1991-05-15 1993-11-16 The Salk Institute For Biological Studies GRF analogs XI
US6916489B2 (en) * 1992-06-15 2005-07-12 Emisphere Technologies, Inc. Active agent transport systems
US6461643B2 (en) * 1993-04-22 2002-10-08 Emisphere Technologies, Inc. Oral drug delivery compositions and methods
US20010003001A1 (en) * 1993-04-22 2001-06-07 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
SE9301667D0 (sv) * 1993-05-14 1993-05-14 Kabi Pharmacia Ab New use
US6297212B1 (en) * 1994-05-31 2001-10-02 Gregory M. Fahy Growth hormone therapy and related methods and pharmaceutical compositions
US5837276A (en) * 1994-09-02 1998-11-17 Delab Apparatus for the delivery of elongate solid drug compositions
CA2158782C (en) * 1994-09-23 2010-01-12 Pierrette Gaudreau Marker for growth hormone-releasing factor receptors
US20020111461A1 (en) * 1999-05-21 2002-08-15 Todd C. Somers Low molecular weight peptidomimetic growth hormone secretagogues
US6458764B1 (en) * 1995-05-26 2002-10-01 Theratechnologies Inc. GRF analogs with increased biological potency
IT1285405B1 (it) * 1995-06-06 1998-06-03 Alza Corp Modificazione di farmaci polipeptidici per accrescere il flusso per elettrotrasporto.
TW432073B (en) * 1995-12-28 2001-05-01 Pfizer Pyrazolopyridine compounds
ATE238063T1 (de) * 1996-01-11 2003-05-15 Upjohn Co Wässrige zusammensetzung mit verzögerter freisetzung, enthaltend rinderwachstumshormon- freisetzungsfaktor
EP0914094A4 (en) * 1996-03-28 2000-03-01 Univ Illinois MATERIALS AND METHOD FOR PRODUCING IMPROVED LIPOSOMAL AGENTS
CA2255865C (en) * 1996-05-24 2008-10-14 The Regents Of The University Of Minnesota Synthesis of soluble beta-sheet forming peptides
NZ334236A (en) * 1996-08-30 2000-06-23 Peptech Ltd Composition comprising GnRH, lecithin and stearin
US6420518B1 (en) * 1997-04-04 2002-07-16 Genetech, Inc. Insulin-like growth factor agonist molecules
US6121416A (en) * 1997-04-04 2000-09-19 Genentech, Inc. Insulin-like growth factor agonist molecules
MY118835A (en) * 1997-04-18 2005-01-31 Ipsen Pharma Biotech Sustained release compositions and the process for their preparation
UA64751C2 (uk) * 1997-06-25 2004-03-15 Пфайзер Продактс Інк. Спосіб лікування інсулінової толерантності речовинами, які посилюють секрецію гормону росту (варіанти) та фармацевтична композиція (варіанти)
WO1998058947A1 (en) * 1997-06-25 1998-12-30 Pfizer Inc. Dipeptide derivatives as growth hormone secretagogues
AU8589998A (en) * 1997-07-24 1999-02-16 Valentis, Inc. Ghrh expression system and methods of use
AUPO930697A0 (en) * 1997-09-19 1997-10-09 Walter And Eliza Hall Institute Of Medical Research, The Catalytic antibodies and a method of producing same
GB9723955D0 (en) * 1997-11-14 1998-01-07 Generic Biolog Limited Improvements in or relating to detection of molecules in samples
EP0922446A1 (en) * 1997-12-03 1999-06-16 Applied Research Systems Ars Holding N.V. Solution-phase site-specific preparation of GRF-PEG conjugates
EP2583675A1 (en) * 1998-02-02 2013-04-24 Trustees Of Tufts College Use of dipeptidylpeptidase inhibitors to regulate glucose metabolism
US20030167531A1 (en) * 1998-07-10 2003-09-04 Russell Douglas A. Expression and purification of bioactive, authentic polypeptides from plants
US6512162B2 (en) * 1998-07-10 2003-01-28 Calgene Llc Expression of eukaryotic peptides in plant plastids
US6057422A (en) * 1998-11-25 2000-05-02 The Administrators Of The Tulane Educational Fund Antagonistic analogs of GH-RH inhibiting IGF-I and -II
US6696063B1 (en) * 1998-12-30 2004-02-24 Applied Research Systems Ars Holding N.V. Treatment of HIV-associated dysmorphia/dysmetabolic syndrome (HADDS) with or without lipodystrophy
JP2002535967A (ja) * 1999-01-06 2002-10-29 ジェネンテック・インコーポレーテッド インシュリン様成長因子（ｉｇｆ）ｉ変異体
WO2000047203A1 (en) * 1999-02-12 2000-08-17 Mqs, Inc. Formulation and system for intra-oral delivery of pharmaceutical agents
US6759393B1 (en) * 1999-04-12 2004-07-06 Pfizer Inc. Growth hormone and growth hormone releasing hormone compositions
US6437101B1 (en) * 1999-05-07 2002-08-20 Akzo Nobel N.V. Methods for protein purification using aqueous two-phase extraction
US6268178B1 (en) * 1999-05-25 2001-07-31 Phage Biotechnology Corp. Phage-dependent super-production of biologically active protein and peptides
US7078514B1 (en) * 1999-06-12 2006-07-18 Michael O. Thorner Chicken growth hormone releasing hormone receptor
GB9915200D0 (en) * 1999-06-29 1999-09-01 Janssen Pharmaceutica Nv Neurotrophic factor receptor
EP1064934A1 (en) * 1999-06-30 2001-01-03 Applied Research Systems ARS Holding N.V. GRF-containing lyophilized pharmaceutical composition
ES2401939T3 (es) * 1999-07-23 2013-04-25 Kenji Kangawa Nuevos péptidos
AU772752B2 (en) * 1999-07-26 2004-05-06 Baylor College Of Medicine Super-active porcine growth hormone releasing hormone analog
US20040192593A1 (en) * 1999-07-26 2004-09-30 Baylor College Of Medicine Protease resistant ti-growth hormone releasing hormone
KR100345214B1 (ko) * 1999-08-17 2002-07-25 이강춘 생체적합성 고분자가 수식된 펩타이드의 비점막 전달
ATE381343T1 (de) * 1999-11-03 2008-01-15 Novo Nordisk As Verwendung eines wachstumshormons oder eines wachstumshormon-sekretion fördernden mittels zur appetit-unterdrückung bzw. sättigungsinduktion
CA2395996A1 (en) * 1999-12-28 2001-07-05 Kaken Pharmaceutical Co., Ltd. Neuroprotective drug
US6866851B1 (en) * 1999-12-28 2005-03-15 Washington University GFRα1-RET specific agonists and methods therefor
US20010020012A1 (en) * 2000-02-01 2001-09-06 Andersen Maibritt Bansholm Use of compounds for the regulation of food intake
EP1278858A2 (en) * 2000-03-24 2003-01-29 Millennium Pharmaceuticals, Inc. 46743 and 27417, novel human acyltransferase family members and uses therefor
US7834141B1 (en) * 2000-03-31 2010-11-16 Theresa Siler-Khodr Non-mammalian GnRH analogs and uses thereof in tumor cell growth regulation and cancer therapy
EP2213743A1 (en) * 2000-04-12 2010-08-04 Human Genome Sciences, Inc. Albumin fusion proteins
US20020061838A1 (en) * 2000-05-17 2002-05-23 Barton Holmquist Peptide pharmaceutical formulations
US6967237B2 (en) * 2000-05-30 2005-11-22 Merck & Co., Inc. Ghrelin analogs
CN1454214A (zh) * 2000-08-02 2003-11-05 赛莱技术公司 具有增高功效的修饰生物肽
CA2422707A1 (en) * 2000-10-05 2002-04-11 Ares Trading S.A. Regioselective liquid phase pegylation
US6750194B1 (en) * 2000-10-23 2004-06-15 The Procter & Gamble Company Methods of identifying compounds for regulating muscle mass or function using vasoactive intestinal peptide receptors
US20030083299A1 (en) * 2000-11-04 2003-05-01 Ferguson Ian A. Non-invasive delivery of polypeptides through the blood-brain barrier
US20030027755A1 (en) * 2000-12-08 2003-02-06 Jian Guan Compositions and methods for the rescue of white matter
US20030074679A1 (en) * 2000-12-12 2003-04-17 Schwartz Robert J. Administration of nucleic acid sequence to female animal to enhance growth in offspring
US20020091090A1 (en) * 2000-12-28 2002-07-11 Cole Bridget M. Somatostatin antagonists and agonists
CU23157A1 (es) * 2001-01-03 2006-07-18 Ct Ingenieria Genetica Biotech COMPOSICION FARMACéUTICA PARA EL TRATAMIENTO DEL DANO TISULAR DEBIDO A FALTA DE IRRIGACION SANGUINEA ARTERIAL
US7264810B2 (en) * 2001-01-19 2007-09-04 Cytos Biotechnology Ag Molecular antigen array
BR0206919A (pt) * 2001-02-02 2004-07-06 Conjuchem Inc Derivados de fator de liberação de hormÈnio de crescimento de longa duração
FR2821359B1 (fr) * 2001-02-27 2003-05-09 Sod Conseils Rech Applic L'heterocarpine, une proteine fixant le ghrh humain
US6890905B2 (en) * 2001-04-02 2005-05-10 Prosidion Limited Methods for improving islet signaling in diabetes mellitus and for its prevention
US20040157227A1 (en) * 2001-05-10 2004-08-12 Chopin Lisa Kerstin Reproductive cancer diagnosis and therapy
EP1260229A3 (en) * 2001-05-18 2002-12-11 Sumitomo Pharmaceuticals Company, Limited Anti-autoimmune composition comprising inhibitors of growth hormone-releasing factor activity
US6858580B2 (en) * 2001-06-04 2005-02-22 Nobex Corporation Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
JP4460892B2 (ja) * 2001-06-21 2010-05-12 ジェネンテック インコーポレイテッド 徐放性組成物
AU2002324909A1 (en) * 2001-09-07 2003-03-24 Baylor College Of Medicine Linear dna fragments for gene expression
AR037038A1 (es) * 2001-10-26 2004-10-20 Baylor College Medicine Una composicion y metodo para alterar la masa corporal magra y las propiedades oseas en un sujeto
PL195917B1 (pl) * 2001-10-31 2007-11-30 Inst Farmaceutyczny Nowe peptydy - analogi ludzkiego hormonu uwalniającego hormon wzrostu
AU2002360387B2 (en) * 2001-11-13 2008-08-07 Emisphere Technologies, Inc. Phenoxy amine compounds and compositions for delivering active agents
WO2003047624A1 (fr) * 2001-12-07 2003-06-12 Kaken Pharmaceutical Co., Ltd. Inhibiteur de migration cellulaire
US7250405B2 (en) * 2002-02-07 2007-07-31 Baylor College Of Medicine Modified pituitary gland development in offspring from expectant mother animals treated with growth hormone releasing hormone therapy
AU2003211163A1 (en) * 2002-02-20 2003-09-09 Regents Of The University Of Minnesota Partial peptide mimetics and methods
CN1638732A (zh) * 2002-03-04 2005-07-13 研究及应用科学协会股份有限公司 含载体肽的缓释药物制剂
CN100491395C (zh) * 2002-04-11 2009-05-27 阿斯比奥制药株式会社 修饰肽的制造方法
AU2002307776A1 (en) * 2002-04-16 2003-10-27 Kamada Ltd. Ultrapure transferrin for pharmaceutical compositions
EP1506786B1 (en) * 2002-05-21 2016-11-23 Daiichi Sankyo Company, Limited Medicinal compositions containing ghrelin
CA2485835C (en) * 2002-05-24 2018-03-06 Restoragen, Inc. Methods and dna constructs for high yield production of polypeptides
US20040014645A1 (en) * 2002-05-28 2004-01-22 Advisys, Inc. Increased delivery of a nucleic acid construct in vivo by the poly-L-glutamate ("PLG") system
AU2003253015A1 (en) * 2002-06-20 2004-01-06 Bionethos Holding Gmbh Method and device for multiplying and differentiating cells in the presence of growth factors and of a biological matrix or of a supporting structure
AU2003249208B2 (en) * 2002-07-16 2010-03-04 Vgx Pharmaceuticals, Llc Codon optimized synthetic plasmids
ATE441429T1 (de) * 2002-07-19 2009-09-15 Cytos Biotechnology Ag Ghrelin-träger-konjugate
TWI331922B (en) * 2002-08-09 2010-10-21 Ipsen Pharma Sas Growth hormone releasing peptides
EP1407779A1 (en) * 2002-10-10 2004-04-14 Gastrotech A/S Use of ghrelin for treating low body weight and body fat in gastrectomized individuals
WO2004105789A1 (en) * 2003-05-29 2004-12-09 Theratechnologies Inc. Grf analog compositions and their use
CA2532821A1 (en) * 2003-07-29 2005-02-17 Ares Trading S.A. Use of human growth hormone in multiple system atrophy
US20050063937A1 (en) * 2003-09-16 2005-03-24 Cheng Li Multiple-arm peptide compounds, methods of manufacture and use in therapy

Also Published As

Publication number Publication date
ZA200502221B (en) 2006-08-30
US20090023646A1 (en) 2009-01-22
NZ539218A (en) 2008-03-28
WO2004027064A2 (en) 2004-04-01
BR0314619A (pt) 2005-08-02
CN1688696A (zh) 2005-10-26
RU2005111253A (ru) 2005-11-20
WO2004027064A3 (en) 2004-11-18
KR20050071498A (ko) 2005-07-07
US20060128615A1 (en) 2006-06-15
JP2006504694A (ja) 2006-02-09
EP1539959A2 (en) 2005-06-15
MXPA05002991A (es) 2005-10-05
CA2496687A1 (en) 2004-04-01
AU2003269631A1 (en) 2004-04-08

Similar Documents

Publication Publication Date Title
NO20051804L (no) GHRH analoger
ES2212485T3 (es) Compuestos peptidicos analogos del glucagon como peptido-1 (7-37),su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
PT1171465E (pt) Analogos de petido inibidor gastrico e sua utilizacao para o tratamento de diabetes
IL210668A0 (en) Glucagon - like - peptide - 2 (glp-2) analogues and pharmaceutical composiitons containing them
JP2007302682A (ja) 副甲状腺ホルモンの類似体
CZ298937B6 (cs) Peptid, který je variantou cásti parathyroidního hormonu a peptidy proteinu, príbuzného parathyroidnímu hormonu
TR200000649T2 (tr) PTHrP analogları kullanılarak kırıkların iyileştirilmesi.
BR9508467A (pt) Composição de matéria peptídeo de ligação de receptor de somatostatina composição farmacéutica e processo para realizar uma cirurgia guiada por radiosótopos ou um procedimento de radiodiagnóstico ou radioterapéutico e para aliviar uma doença relacionada com somatostetina em um animal
JPH10512280A (ja) ＰＴＨおよびＰＴＨｒＰの環式同族体
ATE447858T1 (de) Pharmazeutische zusammensetzung für muskelanabolismus
WO2006113681A3 (en) Plant-derived elastin binding protein ligands and methods of using the same
MXPA04005782A (es) Metodos para inducir la ovulacion usando un modulador de nivel camp no polipeptido.
ATE156492T1 (de) Bombesinanaloge
KR20200014287A (ko) 장기-작용성 gip 펩타이드 유사체
JP2007534613A (ja) レラキシンスーパーファミリーペプチド類似体
CN116802190A (zh) 特异于转铁蛋白受体1（TfR1）的双环肽配体
TW201716432A (zh) 新穎肽與肽衍生物及其用途
DK1515745T3 (da) Anvendelse af forbindelser med biologiskaktivitet af vasoaktivt intestinalt peptid til behandlingen af sarkoidose
CN102405229A (zh) 作为甲状旁腺激素(pth)受体激动剂的短链肽
Raisz et al. Comparison of the effects of a potent synthetic analog of bovine parathyroid hormone with native bPTH-(1-84) and synthetic bPTH-(1-34) on bone resorption and collagen synthesis
NO942919L (no) Fenylalaninanaloger av bombesin
WO2005072277A3 (en) Amidated parathyroid hormone fragments and uses thereof
BR0109279A (pt) Antagonistas de lhrh, sua preparação e aplicação como medicamento
DE60334986D1 (de) Muteine des placental growth factor type 1, herstellungsmethode und anwendung davon
JP3553062B2 (ja) ニューロメジンｂ受容体拮抗物質

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application